Gene therapy for multiple myeloma

  • Adachi Y
  • Yoshio-Hoshino N
  • Nishimoto N
  • 1


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Prognosis of multiple myeloma (MM) remains insufficient despite the intervention of high dose chemotherapy with auto- or allo- hematopoietic stem cell transplantation and the advent of molecular target drugs such as thalidomide, lenalidomide, and bortezomib. Further development or new concepts of therapeutic approaches are still required for MM treatment. Current standard protocol for MM treatment does not include gene delivery method or oncolytic virus approaches. Since MM is a disorder originated from B cell lineage, it involves immunological aspects in both pathogenesis and clinical manifestations. Therefore, the comprehension of immunology as well as oncology is essential to exploit new therapeutic approaches. Recently, novel therapeutic concepts for MM have been emerging. In this review, we present current progress of gene therapy related to MM treatments as well as the overview of MM treatment history. [References: 73]

Author-supplied keywords

  • Animals Cytokines/ge [Genetics] *Cytokines/tu [The

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Yasuo Adachi

  • Naoko Yoshio-Hoshino

  • Norihiro C1 - Include review Nishimoto

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free